Ismael Zamora

Ismael Zamora

Auto-generated profile, based on publicly available information

Ismael Zamora

Lead Molecular Design, S.L.

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2003 in Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
SNSibylle Neuhoff
Sibylle Neuhoff
AUAnna-Lena Ungell
Anna-Lena Ungell
IZIsmael Zamora
Ismael Zamora
PAPer Artursson
Per Artursson

1 November 2006 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
CWCarola M. Wassvik
Carola M. Wassvik
AHAnders G. Holmén
Anders G. Holmén
CBChristel BERGSTRÖM
Christel BERGSTRÖM
IZIsmael Zamora
Ismael Zamora
PAPer Artursson
Per Artursson

10 May 2003 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
IZIsmael Zamora
Ismael Zamora
LALovisa Afzelius
Lovisa Afzelius
GCGabriele Cruciani
Gabriele Cruciani

1 June 2005 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
SNSibylle Neuhoff
Sibylle Neuhoff
AUAnna-Lena Ungell
Anna-Lena Ungell
IZIsmael Zamora
Ismael Zamora
PAPer Artursson
Per Artursson

11 October 2010 in Rapid Communications in Mass Spectrometry
Verified
Journal Article
Closed access
PDF file
BBBritta Bonn
Britta Bonn
CLCarina Leandersson
Carina Leandersson
FFFabien Fontaine
Fabien Fontaine
IZIsmael Zamora
Ismael Zamora

1 April 2001 in Molecular Pharmacology
Verified
Journal Article
Closed access
LALovisa Afzelius
Lovisa Afzelius
IZIsmael Zamora
Ismael Zamora
MRMarianne Ridderström
Marianne Ridderström
TATommy B. Andersson
Tommy B. Andersson
AKAnders Karlén
Anders Karlén
CMCollen Masimirembwa
Collen Masimirembwa
This study describes the generation of a three-dimensional quantitative structure activity relationship (3D-QSAR) model for 29 structurally diverse, competitive CYP2C9 inhibitors defined experimentally from an initial data set of 73 compounds. In parallel, a homology model for CYP2C9 using the rabbit CYP2C5 coordinates was built. For molecules with a known interaction mode with CYP2C9, this homology model, in combination with the docking program GOLD, was used to select conformers to use in the 3D-QSAR analysis. The remaining molecules were docked, and the GRID interaction energies for all conformers proposed by GOLD were calculated. This was followed by a principal component analysis (PCA) of the GRID energies for all conformers of all compounds. Based on the similarity in the PCA plot to the inhibitors with a known interaction mode, the conformer to be used in the 3D-QSAR analysis was selected. The compounds were randomly divided into two groups, the training data set (n = 21) to build the model and the external validation set (n = 8). The PLS (partial least-squares) analysis of the interaction energies against the Ki values generated a model with r2 = 0.947 and a cross-validation of q2 = 0.730. The model was able to predict the entire external data set within 0.5 log units of the experimentalKi values. The amino acids in the active site showed complementary features to the grid interaction energies in the 3D-QSAR model and were also in agreement with mutagenesis studies.